A Phase 3 interventional study of D961H sachet 10 mg and D961H capsule 10mg in Gastric Ulcer (GU), Duodenal Ulcer (DU) and Anastomotic Ulcer (AU), sponsored by AstraZeneca. Completed at 15 sites in Japan. Open to participants aged 1 Year to 14 Years. Per ClinicalTrials.gov, last updated 2017-01-19.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Stomach Ulcer by AstraZeneca — none open to participants now, none under way, none of them phase 3. Stomach Ulcer · AstraZeneca.
Among the 17 studies in Stomach Ulcer by AstraZeneca, this one is the 10th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2014, is one of 11 in phase 3, and was the 16th registered.
116 studies on the registry are indexed under Stomach Ulcer; 13 are open to participants now.
Browse Stomach Ulcer studies →None of the 17 studies in Stomach Ulcer by AstraZeneca is open now. The open studies under Stomach Ulcer, anywhere →
Of the 10 Stomach Ulcer studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 1 Year to 14 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 55 is below the median of 298 across 88 interventional studies indexed under Stomach Ulcer.
Median enrollment 397 across the 13 interventional studies, 1,999 across the 4 observational. Of the 17 that completed or were terminated, 7 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Stomach Ulcer by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to assess the safety, pharmacokinetics, pharmacodynamics and efficacy of repeated once daily oral administration of D961H 10 mg and D961H 20 mg in Japanese paediatric patients aged 1 to 14 years old who either have a diagnosis of or are suspected to have gastric ulcer (GU), duodenal ulcer (DU), anastomotic ulcer (AU), non-erosive reflux esophagitis disease (NERD), reflux esophagitis (RE) or Zollinger-Ellison syndrome.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Age: ≥1 year Weight: \<20 kg
Drug: D961H sachet 10 mg
Age: ≥1 year to 11years Weight: ≥20 kg
Drug: D961H capsule 10mg
Age: ≥1 year to 11years Weight: ≥20 kg
Drug: D961H capsule 20 mg
Age: 12 to 14 years Weight: ≥20 kg
Drug: D961H capsule 10mg
Age: 12 to 14 years Weight: ≥20 kg
Drug: D961H capsule 20 mg
Disappearance of Heartburn at Week 8 by Patient Diaries
The disappearance of heartburn was assessed by the intensity of the symptom at Week 8. Patients who recognized disappearance of heartburn were defined as those who selected "Mild", "Moderate", or "Severe" to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of "None" at Week 8.
Time frame: 8 weeks
Disappearance of Epigastric Pain at Week 8 by Patient Diaries
The disappearance of epigastric pain was assessed by the intensity of the symptom at Week 8. Patients who recognized disappearance of epigastric pain were defined as those who selected "Mild", "Moderate", or "Severe" to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of "None" at Week 8.
Time frame: 8 weeks
Disappearance of Upper Abdominal Discomfort at Week 8 by Patient Diaries
The disappearance of upper abdominal discomfort was assessed by the intensity of the symptom at Week 8. Patients who recognized disappearance of upper abdominal discomfort were defined as those who selected "Mild", "Moderate", or "Severe" to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of "None" at Week 8.
Time frame: 8 weeks
Disappearance of Regurgitation at Week 8 by Patient Diaries
The disappearance of regurgitation was assessed by the intensity of the symptom at Week 8. Patients who recognized disappearance of regurgitation were defined as those who selected "Mild", "Moderate", or "Severe" to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of "None" at Week 8.
Time frame: 8 weeks
Aggravation of Heartburn at Week 8 by Patient Diaries
The aggravation of heartburn was assessed by the intensity of the symptom at Week 8. Patients who recognized aggravation of heartburn were defined as those who selected "None" to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of "Mild", "Moderate" or "Severe" at Week 8.
Time frame: 8 weeks
Aggravation of Epigastric Pain at Week 8 by Patient Diaries
The aggravation of epigastric pain was assessed by the intensity of the symptom at Week 8. Patients who recognized aggravation of epigastric pain were defined as those who selected "None" to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of "Mild", "Moderate" or "Severe" at Week 8.
Time frame: 8 weeks
Aggravation of Upper Abdominal Discomfort at Week 8 by Patient Diaries
The aggravation of upper abdominal discomfort was assessed by the intensity of the symptom at Week 8. Patients who recognized aggravation of upper abdominal discomfort were defined as those who selected "None" to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of "Mild", "Moderate" or "Severe" at Week 8.
Time frame: 8 weeks
Aggravation of Regurgitation at Week 8 by Patient Diaries
The aggravation of regurgitation was assessed by the intensity of the symptom at Week 8. Patients who recognized aggravation of regurgitation were defined as those who selected "None" to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of "Mild", "Moderate" or "Severe" at Week 8.
Time frame: 8 weeks
Disappearance of Heartburn at Week 8 by Investigators
The investigators assessed the presence/absence and the intensity of heartburn at baseline and Week 8 based on questioning the patients or patients' guardians and the patient diary. Patients who recognized disappearance of heartburn were defined as those who had a heartburn at pre-dose and did not have the corresponding symptoms at Week 8 judged by investigators.
Time frame: 8 weeks
Disappearance of Epigastric Pain at Week 8 by Investigators
The investigators assessed the presence/absence and the intensity of epigastric pain at baseline and Week 8 based on questioning the patients or patients' guardians and the patient diary. Patients who recognized disappearance of epigastric pain were defined as those who had an epigastric pain at pre-dose and did not have the corresponding symptoms at Week 8 judged by investigators.
Time frame: 8 weeks
Disappearance of Upper Abdominal Discomfort at Week 8 by Investigators
The investigators assessed the presence/absence and the intensity of upper abdominal discomfort at baseline and Week 8 based on questioning the patients or patients' guardians and the patient diary. Patients who recognized disappearance of upper abdominal discomfort were defined as those who had an upper abdominal discomfort at pre-dose and did not have the corresponding symptoms at Week 8 judged by investigators.
Time frame: 8 weeks
Disappearance of Regurgitation at Week 8 by Investigators
The investigators assessed the presence/absence and the intensity of regurgitation at baseline and Week 8 based on questioning the patients or patients' guardians and the patient diary. Patients who recognized disappearance of regurgitation were defined as those who had a regurgitation at pre-dose and did not have the corresponding symptoms at Week 8 judged by investigators.
Time frame: 8 weeks
Aggravation of Heartburn at Week 8 by Investigators
The investigators assessed the presence/absence and the intensity of heartburn at baseline and Week 8 based on questioning the patients or patients' guardians and the patient diary. Patients who recognized aggravation of heartburn were defined as those who had no heartburn at pre-dose and did have any of the corresponding symptoms at Week 8 judged by investigators.
Time frame: 8 weeks
Aggravation of Epigastric Pain at Week 8 by Investigators
The investigators assessed the presence/absence and the intensity of epigastric pain at baseline and Week 8 based on questioning the patients or patients' guardians and the patient diary. Patients who recognized aggravation of epigastric pain were defined as those who had no epigastric pain at pre-dose and did have any of the corresponding symptoms at Week 8 judged by investigators.
Time frame: 8 weeks
Aggravation of Upper Abdominal Discomfort at Week 8 by Investigators
The investigators assessed the presence/absence and the intensity of upper abdominal discomfort at baseline and Week 8 based on questioning the patients or patients' guardians and the patient diary. Patients who recognized aggravation of upper abdominal discomfort were defined as those who had no upper abdominal discomfort at pre-dose and did have any of the corresponding symptoms at Week 8 judged by investigators.
Time frame: 8 weeks
Aggravation of Regurgitation at Week 8 by Investigators
The investigators assessed the presence/absence and the intensity of regurgitation at baseline and Week 8 based on questioning the patients or patients' guardians and the patient diary. Patients who recognized aggravation of regurgitation were defined as those who had no regurgitation at pre-dose and did have any of the corresponding symptoms at Week 8 judged by investigators.
Time frame: 8 weeks
Area Under the Plasma Concentration-time Curve During a Dosing Interval (AUCtau) of Esomeprazole After at Least 5 Days of Repeated Dose
Time frame: 0, 0.5, 1, 1.5, 2, 3, 4 and 6 hours post-dose after at least 5 days of repeated dose
AUC From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of Esomeprazole After at Least 5 Days of Repeated Dose
Time frame: 0, 0.5, 1, 1.5, 2, 3, 4 and 6 hours post-dose after at least 5 days of repeated dose
Maximum Plasma Concentration (Cmax) of Esomeprazole After at Least 5 Days of Repeated Dose
Time frame: 0, 0.5, 1, 1.5, 2, 3, 4 and 6 hours post-dose after at least 5 days of repeated dose
Time to Reach Maximum Plasma Concentration (Tmax) of Esomeprazole After at Least 5 Days of Repeated Dose
Time frame: 0, 0.5, 1, 1.5, 2, 3, 4 and 6 hours post-dose after at least 5 days of repeated dose
Elimination Half-life (t1/2) of Esomeprazole After at Least 5 Days of Repeated Dose
Time frame: 0, 0.5, 1, 1.5, 2, 3, 4 and 6 hours post-dose after at least 5 days of repeated dose
Apparent Total Clearance (CL/F) of Esomeprazole After at Least 5 Days of Repeated Dose
Time frame: 0, 0.5, 1, 1.5, 2, 3, 4 and 6 hours post-dose after at least 5 days of repeated dose
Apparent Volume of Distribution (Vz/F) of Esomeprazole After at Least 5 Days of Repeated Dose
Time frame: 0, 0.5, 1, 1.5, 2, 3, 4 and 6 hours post-dose after at least 5 days of repeated dose
First subject enrolled on 24 June 2014 Last subject last visit on 04 April 2016. This study was conducted at a total of 20 sites in Japan.
| Milestone | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| Started | 10 | 10 | 10 | 10 | 10 |
| Completed | 9 | 10 | 9 | 9 | 10 |
| Not completed | 1 | 0 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 1 | 0 |
The disappearance of heartburn was assessed by the intensity of the symptom at Week 8. Patients who recognized disappearance of heartburn were defined as those who selected "Mild", "Moderate", or "Severe" to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of "None" at Week 8.
| Participants | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| Disappearance of Heartburn at Week 8 by Patient Diaries | 2 | 0 | 0 | 1 | 3 |
The disappearance of epigastric pain was assessed by the intensity of the symptom at Week 8. Patients who recognized disappearance of epigastric pain were defined as those who selected "Mild", "Moderate", or "Severe" to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of "None" at Week 8.
| Participants | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| Disappearance of Epigastric Pain at Week 8 by Patient Diaries | 2 | 3 | 5 | 1 | 3 |
The disappearance of upper abdominal discomfort was assessed by the intensity of the symptom at Week 8. Patients who recognized disappearance of upper abdominal discomfort were defined as those who selected "Mild", "Moderate", or "Severe" to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of "None" at Week 8.
| Participants | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| Disappearance of Upper Abdominal Discomfort at Week 8 by Patient Diaries | 3 | 2 | 4 | 2 | 2 |
The disappearance of regurgitation was assessed by the intensity of the symptom at Week 8. Patients who recognized disappearance of regurgitation were defined as those who selected "Mild", "Moderate", or "Severe" to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of "None" at Week 8.
| Participants | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| Disappearance of Regurgitation at Week 8 by Patient Diaries | 3 | 2 | 3 | 2 | 4 |
The aggravation of heartburn was assessed by the intensity of the symptom at Week 8. Patients who recognized aggravation of heartburn were defined as those who selected "None" to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of "Mild", "Moderate" or "Severe" at Week 8.
| participants | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| Aggravation of Heartburn at Week 8 by Patient Diaries | 0 | 0 | 0 | 0 | 0 |
The aggravation of epigastric pain was assessed by the intensity of the symptom at Week 8. Patients who recognized aggravation of epigastric pain were defined as those who selected "None" to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of "Mild", "Moderate" or "Severe" at Week 8.
| participants | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| Aggravation of Epigastric Pain at Week 8 by Patient Diaries | 0 | 0 | 1 | 1 | 1 |
The aggravation of upper abdominal discomfort was assessed by the intensity of the symptom at Week 8. Patients who recognized aggravation of upper abdominal discomfort were defined as those who selected "None" to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of "Mild", "Moderate" or "Severe" at Week 8.
| participants | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| Aggravation of Upper Abdominal Discomfort at Week 8 by Patient Diaries | 0 | 0 | 2 | 1 | 0 |
The aggravation of regurgitation was assessed by the intensity of the symptom at Week 8. Patients who recognized aggravation of regurgitation were defined as those who selected "None" to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of "Mild", "Moderate" or "Severe" at Week 8.
| participants | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| Aggravation of Regurgitation at Week 8 by Patient Diaries | 2 | 0 | 1 | 0 | 0 |
The investigators assessed the presence/absence and the intensity of heartburn at baseline and Week 8 based on questioning the patients or patients' guardians and the patient diary. Patients who recognized disappearance of heartburn were defined as those who had a heartburn at pre-dose and did not have the corresponding symptoms at Week 8 judged by investigators.
| Participants | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| Disappearance of Heartburn at Week 8 by Investigators | 2 | 1 | — | 2 | 2 |
The investigators assessed the presence/absence and the intensity of epigastric pain at baseline and Week 8 based on questioning the patients or patients' guardians and the patient diary. Patients who recognized disappearance of epigastric pain were defined as those who had an epigastric pain at pre-dose and did not have the corresponding symptoms at Week 8 judged by investigators.
| Participants | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| Disappearance of Epigastric Pain at Week 8 by Investigators | 2 | 5 | 4 | 2 | 6 |
The investigators assessed the presence/absence and the intensity of upper abdominal discomfort at baseline and Week 8 based on questioning the patients or patients' guardians and the patient diary. Patients who recognized disappearance of upper abdominal discomfort were defined as those who had an upper abdominal discomfort at pre-dose and did not have the corresponding symptoms at Week 8 judged by investigators.
| Participants | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| Disappearance of Upper Abdominal Discomfort at Week 8 by Investigators | 3 | 5 | 4 | 4 | 3 |
The investigators assessed the presence/absence and the intensity of regurgitation at baseline and Week 8 based on questioning the patients or patients' guardians and the patient diary. Patients who recognized disappearance of regurgitation were defined as those who had a regurgitation at pre-dose and did not have the corresponding symptoms at Week 8 judged by investigators.
| Participants | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| Disappearance of Regurgitation at Week 8 by Investigators | 3 | 0 | 3 | 1 | 3 |
The investigators assessed the presence/absence and the intensity of heartburn at baseline and Week 8 based on questioning the patients or patients' guardians and the patient diary. Patients who recognized aggravation of heartburn were defined as those who had no heartburn at pre-dose and did have any of the corresponding symptoms at Week 8 judged by investigators.
| Participants | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| Aggravation of Heartburn at Week 8 by Investigators | 0 | 0 | 0 | 1 | 0 |
The investigators assessed the presence/absence and the intensity of epigastric pain at baseline and Week 8 based on questioning the patients or patients' guardians and the patient diary. Patients who recognized aggravation of epigastric pain were defined as those who had no epigastric pain at pre-dose and did have any of the corresponding symptoms at Week 8 judged by investigators.
| Participants | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| Aggravation of Epigastric Pain at Week 8 by Investigators | 0 | 0 | 0 | 0 | 0 |
The investigators assessed the presence/absence and the intensity of upper abdominal discomfort at baseline and Week 8 based on questioning the patients or patients' guardians and the patient diary. Patients who recognized aggravation of upper abdominal discomfort were defined as those who had no upper abdominal discomfort at pre-dose and did have any of the corresponding symptoms at Week 8 judged by investigators.
| Participants | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| Aggravation of Upper Abdominal Discomfort at Week 8 by Investigators | 0 | 0 | 0 | 1 | 0 |
The investigators assessed the presence/absence and the intensity of regurgitation at baseline and Week 8 based on questioning the patients or patients' guardians and the patient diary. Patients who recognized aggravation of regurgitation were defined as those who had no regurgitation at pre-dose and did have any of the corresponding symptoms at Week 8 judged by investigators.
| Participants | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| Aggravation of Regurgitation at Week 8 by Investigators | 0 | 0 | 1 | 0 | 1 |
| μmol*h/L | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve During a Dosing Interval (AUCtau) of Esomeprazole After at Least 5 Days of Repeated Dose | 7.04 ± 3.05 | 3.52 ± 2.35 | 11.05 ± 5.11 | 2.38 ± 1.74 | 5.82 ± 1.85 |
| μmol*h/L | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| AUC From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of Esomeprazole After at Least 5 Days of Repeated Dose | 5.53 ± 3.69 | 3.09 ± 2.34 | 10.41 ± 4.55 | 1.99 ± 1.30 | 5.45 ± 1.78 |
| μmol/L | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of Esomeprazole After at Least 5 Days of Repeated Dose | 3.42 ± 2.09 | 2.09 ± 1.53 | 5.91 ± 2.19 | 1.09 ± 0.57 | 3.13 ± 1.36 |
| hour | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| Time to Reach Maximum Plasma Concentration (Tmax) of Esomeprazole After at Least 5 Days of Repeated Dose | 1.58 ± 2.09 | 1.52 ± 1.53 | 1.47 ± 2.19 | 1.57 ± 0.57 | 1.75 ± 1.36 |
| hour | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| Elimination Half-life (t1/2) of Esomeprazole After at Least 5 Days of Repeated Dose | 0.80 ± 0.18 | 0.97 ± 0.55 | 1.08 ± 0.44 | 1.37 ± 0.88 | 1.06 ± 0.25 |
| L/h | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| Apparent Total Clearance (CL/F) of Esomeprazole After at Least 5 Days of Repeated Dose | 4.74 ± 1.92 | 12.44 ± 8.90 | 6.44 ± 3.37 | 23.33 ± 24.93 | 10.94 ± 3.64 |
| L | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| Apparent Volume of Distribution (Vz/F) of Esomeprazole After at Least 5 Days of Repeated Dose | 5.10 ± 1.24 | 16.56 ± 16.21 | 9.21 ± 4.00 | 44.73 ± 72.03 | 15.90 ± 4.42 |
Collected over Serious adverse events were collected from the date of signing of informed consent to 8 weeks or withdrawal. Other adverse events were collected from the start of investigational drug administration to 8 weeks or withdrawal.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1 | — | 2/10 (20%) | 8/10 (80%) |
| Group 2 | — | 0/10 (0%) | 8/10 (80%) |
| Group 3 | — | 0/10 (0%) | 5/10 (50%) |
| Group 4 | — | 0/10 (0%) | 5/10 (50%) |
| Group 5 | — | 1/10 (10%) | 6/10 (60%) |
| Event | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| Anaphylactic reactionImmune system disorders | 1/10 | 0/10 | 0/10 | 0/10 | 0/10 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/10 | 0/10 | 0/10 | 0/10 | 0/10 |
| Irritable bowel syndromeGastrointestinal disorders | 0/10 | 0/10 | 0/10 | 0/10 | 1/10 |
| Event | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 1/10 | 4/10 | 2/10 | 1/10 | 3/10 |
| PneumoniaInfections and infestations | 2/10 | 0/10 | 0/10 | 0/10 | 0/10 |
| HeadacheNervous system disorders | 0/10 | 2/10 | 0/10 | 0/10 | 2/10 |
| DiarrhoeaGastrointestinal disorders | 1/10 | 0/10 | 2/10 | 0/10 | 1/10 |
| NauseaGastrointestinal disorders | 0/10 | 1/10 | 0/10 | 0/10 | 2/10 |
| VomitingGastrointestinal disorders | 2/10 | 0/10 | 0/10 | 0/10 | 0/10 |
| BronchitisInfections and infestations | 1/10 | 0/10 | 0/10 | 0/10 | 0/10 |
| GastroenteritisInfections and infestations | 1/10 | 0/10 | 0/10 | 0/10 | 1/10 |
| Gastroenteritis viralInfections and infestations | 0/10 | 0/10 | 0/10 | 1/10 | 0/10 |
| InfluenzaInfections and infestations | 0/10 | 1/10 | 0/10 | 0/10 | 0/10 |
| Age, Continuous(Years) | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 | Total |
|---|---|---|---|---|---|---|
| Mean | 3.6 ± 2.2 | 8.9 ± 0.7 | 8.4 ± 1.8 | 13.4 ± 0.7 | 13.1 ± 0.9 | 9.5 ± 3.9 |
| Age, Customized(Participants) | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 | Total |
|---|---|---|---|---|---|---|
| <= 3 years | 5 | 0 | 0 | 0 | 0 | 5 |
| 4-5 years | 2 | 0 | 0 | 0 | 0 | 2 |
| 6-7 years | 3 | 0 | 4 | 0 | 0 | 7 |
| 8-9 years | 0 | 8 | 3 | 0 | 0 | 11 |
| 10-11 years | 0 | 2 | 3 | 0 | 0 | 5 |
| 12-14 years | 0 | 0 | 0 | 10 | 10 | 20 |
| Gender(Participants) | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 | Total |
|---|---|---|---|---|---|---|
| Female | 5 | 6 | 2 | 7 | 6 | 26 |
| Male | 5 | 4 | 8 | 3 | 4 | 24 |
The record gives a start of Jun 2014, a primary completion of Apr 2016 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2017, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: D961H